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Objectives: This study tested 2 hypotheses: (1) chemotherapy in-
creases the rate of cognitive decline in breast and colorectal cancer
patients beyond what is typical of normal aging and (2) chemo-
therapy results in systematic cognitive declines when compared
with breast and colorectal cancer patients who did not receive
chemotherapy.
Subjects: Data came from personal interviews with a prospective
cohort of patients with breast (n = 141) or colorectal cancer
(n = 224) with incident disease drawn from the nationally repre-
sentative Health and Retirement Study (1998–2006) with linked
Medicare claims.
Measures: The 27-point modified Telephone Interview for Cogni-
tive Status was used to assess cognitive functioning, focusing on
memory and attention. We defined the smallest clinically significant
change as 0.4 points per year.
Results: We used Bayesian hierarchical linear models to test the
hypotheses, adjusting for multiple possible confounders. Eighty-
eight patients were treated with chemotherapy; 277 were not. The
mean age at diagnosis was 75.5. Patients were followed for a me-
dian of 3.1 years after diagnosis, with a range of 0 to 8.3 years. We
found no differences in the rates of cognitive decline before and
after diagnosis for patients who received chemotherapy in adjusted
models (P = 0.86, one-sided 95% posterior intervals lower bound:
0.09 worse after chemotherapy), where patients served as their own
controls. Moreover, the rate of cognitive decline after diagnosis did
not differ between patients who had chemotherapy and those who
did not (P = 0.84, one-sided 95% posterior intervals lower bound:
0.11 worse for chemotherapy group in adjusted model).
Conclusions: There was no evidence of cognitive decline asso-
ciated with chemotherapy in this sample of older adults with breast
and colorectal cancer.
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In the United States alone, there are currently >11 millioncancer survivors.1,2 This makes the long-term con-
sequences of cancer treatments an area of substantial public
health concern.3–5 Several studies have shown declines in
self-reported cognitive functioning after chemotherapy6,7;
however, research on the effect of chemotherapy on neuro-
psychological tests has been mixed.8,9 Some prominent
studies have shown small-to-moderate negative effects of
chemotherapy on measures of memory and executive func-
tioning,10–18 whereas others have shown no chemotherapy-
based cognitive declines.19–24 However, these studies have
primarily included younger women.
Older adults are at an increased risk of dementia,25 and
having cancer is a risk factor for long-term cognitive defi-
cits.26,27 Thus, chemotherapy could have a greater effect on
cognitive function in older adults. Yet, few studies to date
have examined older adults, and the results of these studies
have been mixed.28,29 Given that older adults with cognitive
impairment require greater care30 and have higher mortality
rates,31 there is a great need to establish whether chemo-
therapy has enduring cognitive side effects in older adults.
To address this need, we took advantage of a unique,
prospectively collected assessment of cognitive function in
the Health and Retirement Study (HRS) linked to Medicare
claims data to test 2 hypotheses about the long-term effect of
chemotherapy on cognitive functioning. First, we tested the
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hypothesis that for patients who receive chemotherapy, the
rate of cognitive decline after treatment would be greater
than their rate of cognitive decline before the receipt of
chemotherapy. Second, we hypothesized that the rate of
cognitive decline after diagnosis would be greater for pa-
tients who receive chemotherapy than for cancer patients
who did not have chemotherapy while simultaneously con-
trolling for other risk factors for cognitive decline.
METHODS
Settings and Participants
The HRS is a longitudinal panel study that surveys
a nationally representative sample of Americans over the
age of 50 every 2 years about a wide array of topics, in-
cluding detailed questions about their cognitive function.32
On turning 65, most of the cohort consented to link
their Medicare administrative data with the HRS interview
data.
We examined all respondents who had cognitive test-
ing in the HRS-Medicare cohort between 1998 and 2004.
Within this group, we identified patients with incident breast
or colorectal cancer using Medicare claims from 1998
through 2006. We chose to focus on these 2 types of cancer
because of their high incidence and high survivability. In-
cident breast cancer cases were identified via the validated
Nattinger algorithm.33,34 Incident colorectal cancer cases
were defined by the method of Yabroff,35 where we excluded
prevalent cases by requiring no previous colorectal cancer
claims in the prior 1095 days.36
Chemotherapy was defined by the presence of claims
for chemotherapy infusion, using a validated method.37
Outpatient chemotherapy was defined for both types of
cancer by the occurrence of Healthcare Common Procedure
Coding System codes in an outpatient or carrier file or the
inpatient file; the relevant codes are included in Supple-
mental Digital Content 1, http://links.lww.com/MLR/A303.
These codes were identified by independent review of all
Medicare-covered infusion drugs by a medical oncologist
(J.J.G.) and an internist (T.J.I.).
We required at least 1 cognitive status examination
before diagnosis and continuous enrollment in fee-for-serv-
ice Medicare, to ensure full claims data were present. Date of
diagnosis was inferred as the earliest inpatient or outpatient
claim date associated with cancer. The time between diag-
nosis and the last cognitive status examination before diag-
nosis varied by respondent; median length was 360 days,
with a range of 2 to 3394 days. All patients were followed
through death or the 2006 HRS survey. These inclusion
criteria resulted in a minimum of 1 observation (before
cancer diagnosis) and a maximum of 6 observations per
respondent. Observations were collected every 2 years re-
sulting in a maximum follow-up time of 9 years (eg, patient
diagnosed in 1998 immediately after 1998 observation with
follow-up data from 2000 to 2006 collected every 2 y). The
timing of diagnosis varied between patients ranging from 5
observations before diagnosis and 1 after to 1 observation
before diagnosis to 5 after.
Outcomes
Cognitive function was measured using a modified ver-
sion of the Telephone Interview for Cognitive Status (TICS-m),
which was developed from 2 well-validated scales: (1) the
original TICS measure and (2) the Mini-Mental State Exami-
nation. The TICS-m, validated on large nationally representative
samples, has been shown to have satisfactory psychometric
properties and to correlate with important sociodemographic and
health characteristics in predictable ways38,39 and has been
successfully used to document the effects of other diseases on
long-term cognitive function.40,41 More information on the HRS
cognitive scale is available at the HRS Web site.42 HRS re-
spondents represented by a proxy are not administered the
cognitive scale. Therefore, data from proxies were excluded
from our primary analysis, resulting in the loss of 8% of all
observations. Using data for the full HRS sample, we calculated
that among 65-year-olds, TICS-m scores declined by an average
of 0.55 points over 3 years, by 0.92 points over 5 years, and by
1.84 points over 10 years, or approximately 0.18 points per year.
Using this pattern of cognitive decline for “normal aging,” we
defined a change of 0.4 points per year as the minimum clin-
ically significant change in TICS-m scores, with lower scores
indicating declines in cognitive function. This magnitude
of change would indicate that 1 year of cognitive decline due
to chemotherapy approximates 2 years of “normal” cognitive
decline.
Analyses
To examine the impact of chemotherapy on cognitive
functioning, we studied the psychometric properties of the
TICS-m for our specific population of interest (individuals in
the HRS with breast or colorectal cancer). We then estimated
several hierarchical longitudinal models of patients’ TICS-m
scores, which allow these scores to have one pattern of
change before diagnosis and a second pattern of change after
diagnosis. These models used TICS-m score as the outcome
and time, diagnosis (before/after), and chemotherapy receipt
(receive/did not receive) as predictors. To develop the un-
adjusted model, we tested several linear and nonlinear hier-
archical longitudinal models that included these predictor
variables and their interactions. Models were assessed using
the restricted maximum likelihood estimate with the lme4
package in R43 and using the Markov chain Monte Carlo
method with the rjags package in R.44 The best model,
as judged by AIC (Akaike Information Criterion), BIC
(Bayesian Information Criterion), and deviance, is described
and expanded upon below; our results were not sensitive to
model choice. After the selection of the best fitting un-
adjusted model, we estimated the same model while adjust-
ing for effects of age, body mass index, Charlson score,
activities of daily living, instrumental activities of daily
living, education, income, tobacco and alcohol use, and
census region. The covariates were chosen because of their
known relationships with cognitive functioning and/or ad-
ministration of chemotherapy.38,45,46 In the adjusted model,
the covariates were treated as fixed-effects, and effects were
estimated separately on the slope and on the intercept of the
growth curve as well as on the interaction between chemo-
therapy receipt and time. For all models, we used one-tailed
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tests of the hypothesis that chemotherapy is associated with
declines in cognitive function; therefore we report only the
lower bound of all posterior intervals.
In addition to these primary analyses, we replicated 4
versions of this model to determine whether our conclusions
were robust to a variety of confounders. We tested (1)
whether the exclusion of proxies influenced our results by
setting cognition score to zero when a proxy was used, (2)
whether the chemotherapy group was substantively different
from the control group before treatment using a propensity
matching approach, (3) whether only short-term effects of
chemotherapy existed by analyzing only the observation
immediately after diagnosis, and (4) whether a continuous or
categorical interpretation of the TICS-m affected the results.
We also used data simulation to estimate the probability of
obtaining our results, assuming existence of a minimum
clinically significant change on the TICS-m defined above.
That is, we estimated the probability that we would obtain
the reported results if chemotherapy truly decreased cogni-
tive function by 0.4 points per year. This is essentially a post
hoc power calculation under the hypothesis of a minimum
clinically significant change. Details of these models are
presented in Appendix.
In the frequentist analyses, a P-value of 0.05 was
considered significant. Because we also estimated Bayesian
models, we report 95% posterior intervals (PI) rather than
confidence intervals, although they are similar in that both
provide ranges of plausible values for the parameter tested.
This work was approved by the University of Michigan
Institutional Review Board. Participants provided informed
consent on enrollment in the HRS and again for linkage to
Medicare claims.
RESULTS
Of the 16,772 respondents in the HRS-Medicare data,
we identified 141 breast and 224 colorectal cancer patients
with incident disease between 1998 and 2006, 24% (n = 88)
of whom received chemotherapy. Of the 365 patients, only
255 had cognitive status examinations after diagnosis (61 of
chemotherapy patients had cognitive examinations). Those
patients were followed for a median of 3.1 years after di-
agnosis and up to 8.3 years afterwards. There were few
significant differences between the chemotherapy and non-
chemotherapy groups before diagnosis; Table 1. Figure 1
depicts the mean TICS-m score at each observation for the
chemotherapy and no chemotherapy groups. Negative num-
bers represent observations before diagnosis, and positive
numbers represent observations after diagnosis. Very few
patients have >3 observations before or after diagnosis.
Therefore, Figure 1 was limited to 3 observations before and
after diagnosis. Both groups exhibited declines in cognitive
functioning at a rate of 0.27 points per year before diagnosis
(P < 0.01, 95% PI: 0.29, 0.14) with no significant dif-
ference in rate of change between patients who eventually
received chemotherapy and those who did not (P = 0.28, 95%
PI: 0.13, 0.33).
As applied to the current population, we studied the
psychometric properties of the TICS-m by fitting a 1-factor
model to the 4 items making up the scale. In this analysis, we
used all data observed at the wave immediately before in-
dividuals’ cancer diagnosis. In fitting the 1-factor model to
the data, we rejected the hypothesis of exact fit (w2(2) = 10.5,
P < 0.05). The hypothesis of exact fit is often rejected at
larger sample sizes, so we also examined the Root Mean
Square Error of Approximation (RMSEA). The 90% con-
fidence interval for the RMSEA was (0.053, 0.184), which
implies a range from “reasonable fit” to “poor fit.”47 The pro-
portion of explained common variance was 0.65, Cronbach’s
TABLE 1. Sample Characteristics at Observation Before Breast















Mean (SD) 70.5 (5.3) 72.4 (7.9) 75.8 (7.5) 77.3 (9)
Median 69.3 72 75.7 79.6
Charlson scorew
Mean (SD) 0.8 (1.4) 1.2 (1.7) 1.2 (1.4) 2.2 (2.6)
Median 0 1 1 2
TICS-m scorez
Mean (SD) 15.8 (4.1) 14.8 (4.6) 15.3 (4.3) 13.4 (4.1)




21 (88%) 50 (78%) 91 (78%) 107 (67%)
Limitations before
cancer
3 (12%) 14 (22%) 26 (22%) 53 (33%)
Instrumental ADL, n (%)
No limitations
before cancer
22 (92%) 54 (84%) 102 (87%) 120 (75%)
Limitations before
cancer
2 (8%) 10 (16%) 15 (13%) 40 (25%)
Education, n (%)y
High school or less 8 (33%) 23 (36%) 24 (21%) 51 (32%)
Some college 5 (21%) 17 (27%) 53 (45%) 70 (44%)
College graduate 11 (46%) 24 (38%) 40 (34%) 39 (24%)
Tobacco user, n (%)
Never 13 (54%) 25 (39%) 60 (51%) 71 (44%)
Former 7 (29%) 30 (47%) 40 (34%) 69 (43%)
Current 4 (17%) 9 (14%) 16 (14%) 18 (11%)
Missing 0 (0%) 0 (0%) 1 (1%) 2 (1%)
Alcohol, n (%)
0 d/wk 18 (75%) 49 (77%) 79 (68%) 125 (78%)
< 1 d/wk 0 (0%) 3 (5%) 10 (9%) 9 (6%)
1–2 d/wk 2 (8%) 3 (5%) 3 (3%) 3 (2%)
> 2 d/wk 4 (17%) 9 (14%) 25 (21%) 23 (14%)
Census region, n (%)
1 2 (8%) 11 (17%) 23 (20%) 26 (16%)
2 6 (25%) 24 (38%) 29 (25%) 53 (33%)
3 13 (54%) 25 (39%) 46 (39%) 62 (39%)
4 3 (12%) 4 (6%) 19 (16%) 19 (12%)
Net worth
Mean 907 303 443 276
Median 213 162 184 96
Chemotherapy and no chemotherapy groups differed significantly in:
*Age, t (363) = 4.83, P < 0.001.
wCharlson score, t (363) = 2.62, P = 0.01.
zLower scores on the TICS indicate declines in cognitive function.
yEducation, w2(2) = 10.6, P = 0.005.
ADL indicates activities of daily living, TICS, Telephone Interview for Cognitive
Status.
Medical Care  Volume 50, Number 10, October 2012 Chemotherapy Was Not Associated With Cognitive Decline
r 2012 Lippincott Williams & Wilkins www.lww-medicalcare.com | 851
a was 0.62, and the corrected item-total correlations ranged
from 0.33 to 0.86. The misfit was mainly due to 2 tasks
(serial 7 and backwards counting) that accounted for only 7
points on the 27-point scale, so we elected to use the full
scale in the analyses below. However, the substantive results
described below hold for each of the 4 individual items
making up the TICS-m.
We used 2 strategies to test for the presence of che-
motherapy-associated cognitive declines. First, using a pro-
spective approach, we compared rates of decline in cognitive
function before and after diagnosis for patients receiving
chemotherapy and found no significant differences in either
the unadjusted (P = 0.86, one-sided 95% PI lower bound:
0.12 worse for chemotherapy group) or adjusted models
(P = 0.86, one-sided 95% PI lower bound: 0.09 worse for
chemotherapy group). Second, using a cohort approach, we
compared rates of decline in cognitive function after diag-
nosis between those who received chemotherapy and those
who did not. We found no significant differences in either the
unadjusted (P = 0.85, one-sided 95% PI lower bound: 0.12
worse for chemotherapy group) or the adjusted models
(P = 0.84, one-sided 95% PI lower bound: 0.11 worse for
chemotherapy group) (Table 2). We also estimated the ad-
justed model with the entire HRS-cohort and found that
cognitive function declined at a rate of 0.28 points per year
(z = 8.8, P < 0.05, SE = 0.03); this value was very similar to
the rate of change for cancer patients.
Our results were robust to a variety of confounders.
First, instead of excluding proxies in the analyses, we in-
cluded proxies in the sample and set their cognitive function
scores to zero, thereby allowing us to test whether excluding
proxies gave an unfair advantage to the null hypothesis. Even
in such an extreme case, the model still ruled out all chemo-
therapy-based cognitive declines (P = 0.95, one-sided 95% PI
lower bound: 0.08 better for chemotherapy group). In fact,
nonchemotherapy patients utilized proxy respondents more
often, so if proxy use was informative about poor cognitive
functioning, it would provide yet stronger evidence against a
chemotherapy-associated decline. In addition, we considered
the possibility that (1) the chemotherapy group was sub-
stantively different from the control group, (2) chemotherapy
affected cognitive function only at the first observation after
diagnosis, and (3) categorical measures of cognitive function
would yield different results than our continuous measure.
We used 3 additional modeling approaches to test these al-
ternative explanations, Supplemental Digital Content 2–5,
http://links.lww.com/MLR/A304. The same general pattern
emerged across all models: with 95% certainty, we can ex-
clude declines in cognitive function associated with che-
motherapy that are >1 year of “normal aging.”
Finally, using the data simulation method described
above, we calculated the probability of obtaining these
results if chemotherapy truly decreased cognitive function by
0.4 points per year (the minimum clinically significant
FIGURE 1. Mean cognition score by survey. Error bars indicate
95% confidence intervals for the SEM. These unadjusted re-
sults show no evidence of greater decline in the group of
patients who received chemotherapy than those who did not.
The numbers on each bar represent the number of patients
contributing data to the observation.
TABLE 2. Parameter Estimates for the Adjusted Hierarchical
Longitudinal Model of TICS-m Scores
Parameters b SE P
Intercept 5.05 3.25 0.12
Time 0.12 0.04 0.00
Chemotherapy receipt 0.52 0.45 0.25
Body mass index 1.75 0.96 0.07
Charlson score 0.42 0.35 0.23
ADL 0.16 0.27 0.56
Instrumental ADL 0.61 0.31 0.05
Age 0.15 0.02 0.00
Education
High school or less Reference
Some college 2.42 0.44 0.00
College graduate 3.54 0.46 0.00
Tobacco user
Never Reference
Former 0.22 0.37 0.54
Current 0.64 0.53 0.22
Alcohol
0 d/wk Reference
< 1 d/wk 0.46 0.38 0.22
1–2 d/wk 0.23 0.52 0.66
> 2 d/wk 0.18 0.34 0.60
Census region
1 Reference
2 0.29 0.48 0.56
3 0.40 0.47 0.39
4 0.04 0.59 0.94
Net worth 0.17 0.05 0.00
Interactions
Timechemotherapy receipt* 0.11 0.10 0.86
Timechemotherapy receiptdiagnosisw 0.17 0.17 0.84
*Term tests whether the change in TICS-m score over time is a function of chemo-
therapy receipt.
wTerm tests whether the differences in the slope of TICS-m scores before or after
cancer diagnosis is a function of chemotherapy receipt. TICS-m scores are allowed to
have different slopes before and after diagnosis.
ADL indicates activities of daily living, TICS, Telephone Interview for Cognitive
Status.
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change). In doing so, we were able to reject the hypothesis
that chemotherapy induces cognitive declines of at least that
magnitude with a certainty of P = 0.05.
DISCUSSION
In this study, which used a prospectively collected
assessment of cognitive function in the HRS linked with
Medicare claims data, we did not find support for either of
our hypotheses. The rate of cognitive decline after diagnosis
did not differ from the rate of cognitive decline before
diagnosis for older Americans with breast or colorectal
cancer. Moreover, the rate of cognitive decline after cancer
diagnosis did not differ between patients who had chemo-
therapy and those who did not. These results were robust in
several sensitivity analyses, and the likelihood of obtaining
these results if clinically significant chemotherapy-based
cognitive declines truly exist was 5%.
Our findings are in contrast to a number of cross-sec-
tional studies, which have reported small-to-moderate effects
of chemotherapy on cognitive functioning.10–18,48–51 How-
ever, these results are in line with other prospective studies
that have shown no long-term impact of chemotherapy on
cognitive function.19–24,48–51 In addition to extending the
findings of other prospective studies to a new measure of
cognitive function, the HRS-Medicare data address the col-
lective weaknesses of prior prospective studies: a lack of
data on cognitive function before diagnosis, limited data on
cognitive function after treatment, short follow-up periods,
and statistical models that do not include longitudinal com-
ponents or individual differences.
There are some limitations of using the TICS-m to
measure cognitive function: (1) the TICS-m is a cognitive
screening measure not a full cognitive assessment; as such, it
is less sensitive to small changes in cognitive function. Yet it
has been successfully used to document the effects of other
diseases on long-term cognitive function40,41; (2) given the
somewhat less than optimal reliability estimates in combi-
nation with relatively small sample sizes, the possibility
of lower detectable effect sizes cannot be ruled out; (3)
the TICS-m largely measures memory and attention52;
additional research is needed to determine whether long-
term declines exist in other domains of cognitive function.
There are also several limitations specific to the use of
Medicare administrative data: (1) Medicare data were only
available for consenting participants, which could bias our
results; (2) although we used validated algorithms to detect
cancer cases in Medicare, this is not the same as clinical
assessment; (3) we were unable to assess second primaries or
recurrences in the chemotherapy-treated group; (4) stage of
disease is not available in the claims data. More generally,
this sample only includes patients with breast and colorectal
cancer; therefore, generalizations of these findings to other
types of cancer treated with other types of chemotherapy
may be limited. We were also unable to examine type or
duration of chemotherapy with this sample size. Although
there may be subpopulations at greater risk for adverse
cognitive effects of chemotherapy,16,17 our analysis speaks to
the lack of an association at the population level. However,
we believe the merits of a longitudinal design with cog-
nitive data collected before cancer diagnosis outweigh the
limitations.
In addition to patient clinical factors and cancer char-
acteristics factors, chemotherapy decisions also include a
consideration of potential treatment toxicity and patient will-
ingness to experience that toxicity for, on occasion, uncertain
benefit.53 Given the importance that patients place on preser-
vation of cognitive function when weighing treatment deci-
sions,54 the information garnered from this study may be useful
to patients and physicians alike. Using a prospectively col-
lected assessment of cognitive function, we found no evidence
of clinically significant declines in memory and attention due
to chemotherapy. Therefore, concerns about chemotherapy
commonly reported in the media may not be justified for most
older breast and colorectal cancer patients.4,5
APPENDIX
We replicated several versions of this model to de-
termine whether our conclusions were robust to a variety of
confounders. First, we considered the fact that excluding
proxies from our sample may have given an unfair advantage
to the null hypothesis if there were a proportionally greater
number of proxy respondents in the chemotherapy group. To
address this, we replicated the adjusted model while in-
cluding proxies in the sample and setting their cognition
scores to zero every time a proxy was used. Second, we
considered the possibility that the chemotherapy group was
substantively different from the control group before treat-
ment. To account for this, we created propensity scores for
obtaining chemotherapy for each individual using all co-
variates from the observation immediately before diagnosis.
Minimum distance matched sampling55 was then carried out,
yielding a matched control patient for each chemotherapy
patient. We then tested for chemotherapy-based cognitive
declines by comparing cognition scores from patients that
received chemotherapy to the newly created matched cohort.
Third, we considered the possibility that chemotherapy-
based cognitive declines only arise immediately after diag-
nosis (ie, the patient takes an initial “hit” and then recovers).
To test for short-term chemotherapy-related declines in
cognition scores, we estimated the original adjusted model
including only the first observation after diagnosis for each
chemotherapy patient. Fourth, we examined whether using a
continuous or categorical measure of cognition score af-
fected interpretations of the findings. The original, adjusted
model used a continuous measure of cognition. Therefore
we fit an additional hierarchical ordinal logistic regression
(ie, proportional odds) model to a trichotomous cognition
measure (normal cognitive functioning, cognitive impair-
ment without dementia, or dementia). The cut points used to
create these categories were based on prior studies with the
HRS data.56–58 Normal was defined as 8–27; cognitive im-
pairment without dementia was 6–7; and dementia was 0–5.
The covariates in the model were the same as the original,
adjusted model.
We also used data simulation to estimate our ability to
detect a chemotherapy-associated decrease in cognition scores
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of 0.4 points per year, which was defined as the minimum
clinically significant change on this measure of cognitive
functioning. To do so, we treated all estimates from our ad-
justed model (ie, the modeling including covariates) as pa-
rameters, with the exception of the estimated effect of
chemotherapy, which we set to the minimum clinically sig-
nificant value of a decline in cognition score of 0.4 points per
year. We then generated 5000 datasets from this model. All
generated datasets matched our observed data on number of
patients, time at which each patient was observed, and number
of patients receiving chemotherapy. We then fit the hier-
archical model described above to each of our 5000 generated
datasets, recording the size of the estimated effect of chemo-
therapy on cognitive functioning for each dataset. We then
determined the proportion of times we observed an estimate of
chemotherapy-based cognitive decline as extreme or greater
than that observed in our adjusted model. In doing so, this
analysis provides the probability of obtaining the reported re-
sults if chemotherapy truly decreased cognitive function by 0.4
points per year (the minimum clinically significant change).
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